Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/3/2025

Diagnosis and Treatment of Synovitis

Clinical Recognition and Diagnosis

  • The American College of Rheumatology suggests that joint swelling not caused by trauma or bony swelling, preferably involving at least two joints, is a key clinical feature of synovitis 3
  • Morning stiffness lasting ≥30 minutes (or ≥1 hour in rheumatoid arthritis) is a characteristic symptom of synovitis 1, 3
  • A positive "squeeze test" suggests hand and foot joint involvement in synovitis 3
  • Refer to rheumatology within 6 weeks of symptom onset if persistent synovitis is suspected, even with normal acute-phase response or negative rheumatoid factor, particularly when small joints of hands or feet are affected, more than one joint is affected, or there is a delay of ≥3 months between symptom onset and seeking medical advice 3, 4, 5

Diagnostic Approach

  • Clinical examination is the primary method for detecting synovitis, and in doubtful cases, ultrasound, power Doppler, and MRI can detect synovitis, bone edema, and erosions not evident on clinical examination 1, 3
  • Measure CRP (preferred over ESR as it is simpler, more reliable, and not age-dependent) to assess disease activity 1
  • Test for rheumatoid factor in suspected rheumatoid arthritis with synovitis, and consider anti-citrullinated protein antibodies if rheumatoid factor is negative and combination therapy is being considered 4, 5

Treatment Algorithm

  • The European League Against Rheumatism recommends starting DMARDs as early as possible in patients at risk of persistent or erosive arthritis, even if they do not yet fulfill classification criteria 3
  • Methotrexate is the anchor drug and should be used first in patients at risk of developing persistent disease 3
  • Systemic glucocorticoids reduce pain and swelling and should be considered as adjunctive (mainly temporary) treatment as part of the DMARD strategy 3
  • The main goal is achieving remission or near-remission, with regular monitoring of disease activity guiding decisions on treatment changes 1, 3
  • Use composite disease activity measures (DAS28, SDAI, or CDAI) to assess treatment response 1
  • Consider biologics when DMARD monotherapy fails to achieve remission 3

Adjunctive Therapies

  • Dynamic exercises, occupational therapy, and hydrotherapy can be applied as adjuncts to pharmaceutical interventions 3
  • Patient education programs addressing pain coping, disability management, and work ability maintenance can be beneficial 3